Menopause and hormone replacement therapy

Female Pelvic Health and Reconstructive Surgery

Volumn , Issue , 2002, Pages 417-474

  Mahajan, Sangeeta T ^a   Pinto, Anil B ^a   Williams, Daniel B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350216686     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (266)

1. World Health Organization. Report of a WHO Scientific Group: Research on the Menopause. Geneva, Switzerland: World Health Organization, 1981. WHO Technical Report Series 670.
2. McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Ann Int Med 1985; 103(3):350-356.
3. Greendale GA, Sowers M. The menopause transition. Endocrin Metab Clin North Am 1997; 26(2):261-277.
4. Oldehave A, Jaszmann LJB, Haspels AA, Everaerd WT. Impact of climacteric on well-being. Am J Obstet Gynecol 1993; 168(3 pt 1):772-780.
5. Brambilla DJ, McKinlay SM. A prospective study of factors affecting age at menopause. J Clin Epidemiol 1989; 42(11):1031-1039.
6. Hammond CB. Menopause and hormone replacement therapy: an overview. Obstet Gynecol 1996; 87(2 suppl):2s-15s.
7. Snieder H, MacGregor AJ, Spector TD. Genes control the cessation of a woman’s reproductive life: a twin study of hysterectomy and age at menopause. J Clin Endocrin Metab 1998; 83(6):1875-1880.
8. Bonadonna G, Valaguss P, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi U. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 1985; 5:95-115.
9. Richards MA, O’Reilly SM, Howell A, George WD, Fentiman IS, Chaudary MA, Crowther D, Rubens RD. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy’s Manchester Trial. J Clin Oncol 1990; 8:2032-2039.
10. Mattison DR, Thorgeirsson SS. Smoking and industrial pollution and their effects on menopause and ovarian cancer. Lancet 1978; 1(8057):187-188.
11. Tappel AL. Vitamin E and selenium protection from in vivo lipid peroxidation. Ann N Y Acad Sci 1980; 355(8057):18-31.
12. Van Noord PAH, Dubas JS, Dorland M, Boersma H, Velde E. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertil Steril 1997; 68(1):95-102.
13. Khaw KT. Epidemiology of the menopause. Br Med J 1992; 48(2):249-261.
14. van Keep PA, Brand PC, Lehert P. Factors affecting the age at menopause. J Biosoc Sci Suppl 1979; (6):37-55.
15. Stanford JL, Hartge P, Brinton LA, Hoover RN, Brookmeyer R. Factors influencing age at natural menopause. J Chron Dis 1987; 40(11):995-1002.
16. McKinlay SM, Brambilla PJ, Posner JG. The normal menopause transition. Maturitas 1992;14(2):103-115.
17. Collett ME, Wertenberger GE, Fiske VM. The effect of age upon the pattern of the menstrual cycle. Feril Steril 1954; 5(5):437-447.
18. Metcalf MG, Livesey JH. Gonadotropin excretion in fertile women: effect of age and the onset of the menopausal transition. J Endocrin 1985; 105(3):357-362.
19. Channing CP, Gagliano P, Hoover DJ, Tanabe K, Batta SK, Sulewski J, Lebech P. Relationship between human follicular fluid inhibin F activity and steroid content. J Clin Endocrinol Metab 1981; 52(6):1193-1198.
20. Swartzman LC, Edelberg R, Kemmann E. Impact of stress on objectively recorded menopausal hot flushes and on flush report bias. Health Psychol 1990; 9(5):529-545.
21. Sherman BM, West JH, Korenman SG. The menopausal transition; analysis of LH, FSH, estradiol and progesterone concentrations during the menstrual cycles of older women. J Clin Endocrinol Metab 1976; 42(4):629-636.
22. MacNaughton J, Banah M, McCloud P, Hee J Burger H. Age related changes in follicle stimulating hormone, luteinizing hormone, estradiol and immunoreactive inhibin in women of reproductive age. Clin Endocrinol 1992; 36(4):339-345.
23. Burger HG, Dudley EC, Hopper JL, Shelley JM, Green A, Smith A, Dennerstein L, Morse C. The endocrinology of the menopausal transition: a cross-sectional study of a population based sample. J Clin Endocrinol Metab 1995; 80(12):3537-3545.
24. Ahmed Ebbiary NA, Lenton EA, Cooke ID. Hypothalamic pituitary ageing: progressive increase in FSH and LH concentrations throughout the reproductive life in regularly menstruating women. Clin Endocrinol (Oxf) 1994; 41(2):199-206.
25. Treolar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967; 12(1):77-127.
26. Reyes FI, Winter JS, Faiman C. Pituitary ovarian relationships preceeding the menopause. I. A cross-sectional study of serum follicle-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels. Am J Obstet Gynecol 1977; 129(5):557-564.
27. Shideler SE, DeVane GW, Kalra PS, Benirschke K, Lasley BL. Ovarian pituitary hormone interactions during the perimenopause. Maturitas 1989; 11:331-339.
28. Vagenakis AG. Endocrine aspects of menopause. Clin Rheumatol 1989; 8(suppl 2):190-251.
29. Judd HL, Judd GE, Lucas WE, Yen SS. Endocrine function of the postmenopausal ovary. Concentrations of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 1974; 39:1020-1024.
30. Meldrum DR, Davidson BJ, Tataryn IV, Judd HL. Changes in circulating steroids with aging in postmenopausal women. Obstet Gynecol 1981; 57(5):624-628.
31. Longcope C, Franz C, Morello C, Baker R, Johnston CC. Steroid and gonadotropin levels in women during the peri-menopausal years. Maturitas 1986; 8(3):189-196.
32. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen in postmenopausal women. J Clin Endocrinol Metab 1973; 36(2):207-214.
33. Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstet Gynecol 1982; 59(6):680-686.
34. Purifoy FE, Kooprano LH, Tatum RW. Steroid hormones and aging: free testosterone and androstenedione in normal females age 20-87 years. Hum Biol 1980; 52(2):181-191.
35. Yen SS, The biology of menopause. J Reprod Med 1977; 18(6):287-296.
36. Ginsberg ES, Hot flashes-physiology, hormonal therapy, and alternative therapies. Obstet Gynecol Clin North Am 1994; 21(2):381-390.
37. Voda AM. Climacteric hot flash. Maturitas 1981; 3:73-90.
38. Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: an hypothesis of flash mechanism. Clin Endocrinol 1985; 22(3):293-312.
39. Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 1998; 70(2):332-337.
40. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990; 592:52-86.
41. Mashchak CA, Kletzky OA, Artal R, Mishell DR. The relation of physiologic changes to subjective symptoms in postmenopausal women with and without hot flushes. Maturitas 1984; 6:301-308.
42. Erlik J, Meldrum DR, Judd HL. Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol 1982; 59:403-407.
43. McKinlay SM, Jefferys M. The menopausal syndrome. Br J Prev Soc Med 1974; 28:108-115.
44. Feldman BM, Voda MA, Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health 1985; 8:261-268.
45. Sherman BM, Wallace RB, Bean JA, Chang Y, Schlabaugh L. The relationship of menopausal hot flushes to medical and reproductive experience. 1981; 36(3):306-309.
46. Chakravarti S, Collins WP, Newton JR, Oram DH, Studd JW. Endocrine changes and symptomatology after oophorectomy in premenopausal women. Br J Obstet Gynaecol 1977; 84(10):769-775.
47. Silva NL, Boulant JA. Effects of testosterone, estradiol, and temperature on neurons in preoptic tissue slices. Am J Physiol 1986; 250(4 pt 2):R625-R632.
48. Walsh B, Schiff I. Vasomotor flushes. Ann N Y Acad Sci 1990; 592:346-356.
49. Woodward S, Freedman RR. The thermoregulatory effects of menopausal hot flashes on sleep. Sleep 1994; 17(6):497-501.
50. Roffward HP. Diagnostic classification of sleep and arousal disorders. Sleep 1979; 2:1-137.
51. Shaver J, Giblin E. Lentz M, Lee K. Sleep patterns and stability in perimenopausal women. Sleep 1988; 11(6):556-561.
52. Schiff I, Regestein Q, Tulchinsky D, Ryan KJ. Effects of estrogens on sleep and psychological status of hypogonadal women. JAMA 1979: 242(22):2405-2407.
53. Savvas M, Bishop J, Laurent G, Watson N, Studd J. Type III collagen content in the skin of postmenopausal women receiving oestradiol and testosterone implants. Br J Obstet Gynaecol 1993; 100(2):154-156.
54. Brincat M, Kabalan S, Studd JW, Moniz CF, de Trafford J, Montgomery J. A study of the decrease of skin collagen content, skin thickness, and bone mass in the postmenopausal women. Obstet Gynecol 1987; 70(6):840-845.
55. Callens A, Vaillant L, Lecomte P, Berson M, Gall Y, Lorette G. Does hormonal skin aging exist? A study of the influence of different hormone therapy regimens on the skin of postmenopausal women using non-invasive measurement techniques. Dermatology 1996; 193(4):289-294.
56. Maheux R, Naud F, Rioux M, Grenier R, Lemay A, Guy J, Langevin M. A randomized double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994; 170(2):642-649.
57. Levin RM, Jacobowitz D, Wein AJ. Autonomic innervation of rabbit urinary bladder following estrogen administration. Urology 1981; 27(5):449-453.
58. Dionne FT, Lesage RL, Dube JY, Tremblay RR. Estrogen binding proteins in rat skeletal and perineal muscles: in vitro and in vivo studies. J Steroid Biochem 1979; 11(2):1073-1080.
59. Ekstrom J, Iosif CS, Malmberg L. Effects of long-term treatment with estrogen and progestrone on in vitro muscle responses of the female rabbit urinary bladder and urethra to autonomic drugs and nerve stimulation. J Urol 1993; 150:1284-1288.
60. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329(11):753-756.
61. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999; 353:571-580.
62. Fantl JA, Cardozo l, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: A meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1994; 83(1):12-18.
63. Zinner NR, Sterling AM, Ritter RC. Role of urethral softness in urinary incontinence. Urology 1980; 16:115-117.
64. Mattingly RF, Davis LE. Primary treatment of anatomic stress urinary incontinence. Clin Obstet Gynaecol 1984; 27:445-458.
65. Diokno AC, Brock BM, Brown D. Prevalence of urinary incontinence and other urological symptoms in the non-institutionalized patient. J Urol 1986; 136:1022-1025.
66. Iosif CS, Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand 1984; 63:257-260.
67. Ouslander JG, Kane RL, Abrass IB. Urinary incontinence in elderly nursing home patients. JAMA 1982; 248:1194-1198.
68. Fantl JA, Wyman JF, McClish DK, Bump RC. Urinary incontinence in communitydwelling women: clinical, urodynamic, and severity characteristics. Am J Obstet Gynecol 1990; 162(4):946-951.
69. Bump RC, Friedman CI. Intraluminal urethral pressure measurements in the female baboon: effects of hormonal manipulation. J Urol 1986; 136:508-511.
70. Bhatia NN, Bergman A, Karram MM. Effects of estrogen on urethral function in women with urinary incontinence. Am J Obstet Gynecol 1989; 160(1):176-181.
71. Hinton P, Tweddell AL, Mayne C. Oral and intravaginal estrogens alone and in combination with alpha adrenergic stimulation in genuine stress incontinence. Int Urogynecol J 1990; 1:80-86.
72. Walter S, Wolf H, Barlebo H. Urinary incontinence in postmenopausal women treated with estrogens. Urol Int 1978; 33:135-143.
73. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329:753-760.
74. Fantl JA, Bump RC, Robinson D, McClish DK, Wyman JF. The Continence Program for Women Research Group. Efficacy of estrogen supplementation in the treatment of urinary incontinence. Obstet Gynecol 1996; 88(5): 745-749.
75. Wilson PD, Faragher B, Butler B, Bu’Lock D, Robinson EL, Brown AD. Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women. Br J Obstet Gynaecol 1987; 94(6): 568-574.
76. Riggs BL, Melton JL. Involutional osteoporosis. N Engl J Med 1986; 314(26):1676-1686.
77. World Health Organization. Assessment of Fracture Risk and Its Application for Postmenopausal Osteoporosis. Geneva, Switzerland: World Health Organization, 1994. Technical Report Series.
78. Melton LJ. Hip fractures: a worldwide problem today and tomorrow. Bone 1993; 14:S1-S8.
79. Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective: how many women have osteoporosis? J Bone Mineral Res 1992; 7(9):1005-1010.
80. Parfitt AM, Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994; 55(3):273-286.
81. Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332(5):305-311.
82. Pacifici R. Estrogen, cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Mineral Res 1996; 11(8):1043-1051.
83. Riggs BL. Overview of osteoporosis. West J Med 1991; 154(1):63-77.
84. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332(12):767-773.
85. Melton LJ, Atkinson EJ, O’Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Mineral Res 1993; 8(10):1227-1233.
86. Miller PD, Bonnick SL, Rosen C. Guidelines for the clinical utilization of bone mass measurement in the adult population. Society for Clinical Densitometry. Calcif Tissue Int 1995; 57:251-252.
87. Price CP, Thompson PW, The role of biochemical tests in the screening and monitoring of osteoporosis. Ann Clin Biochem 1995; 32(pt. 3):244-260.
88. Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, Chestnut CH, Eyre DR. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Mineral Res 1994; 9(2):135-142.
89. Steiger P, Cummings SR, Black DM, Spencer NE, Genant HK. Age-related decreements in bone mineral density in women over 65. J Bone Mineral Res 1992; 7(6):625-632.
90. Cummings SR, Black DM, Nevitt MC, Bronner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM. Bone density at various sites for prediction of hip fractures. Lancet 1993; 341(8837):72-75.
91. Rizzoli R, Slosman D, Bonjour JPH. The role of dual energy x-ray absorptiometry of lumbar spine and proximal femur in the diagnosis and follow-up of osteoporosis. Am J Med 1995; 98(A):33s-36s.
92. Hans D, Dargent-Molina P, Schott AM, Sebert JL, Cormier C, Kotzki PO, Delmas PD, Pouilles JM, Breart G, Meunier PJ. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 1996; 348(9026):511-514.
93. Black DM, Cummings SR, Genant HK, Nevitt MC, Palermo L, Bronner W. Axial and appendicular bone density predict fractures in older women. J Bone Mineral Res 1992; 7(6):633-638.
94. Stewart A, Reid DM, Porter RW. Broadband ultrasound attenuation and dual energy x-ray absorptiometry in patients with hip fractures: which technique discriminates fracture risk? Calcif Tissue Int 1994; 54(6):466-469.
95. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996; 276(17):1389-1396.
96. Nordin BE. Guidelines for bone densitometry. Med J Aust 1994; 160(8):517-520.
97. Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage micronized 17B-estradiol prevents bone loss in postmenopausal women. J Obstet Gynecol 1992; 166:479-488.
98. Ettinger B, Gennat HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 1987; 106(1):40-45.
99. Field CS, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL. Preventive effects of transdermal 17B-estradiol on osteoporotic changes after surgical menopause: a two year placebo-controlled trial. AM J Obstet Gynecol 1993; 168(1 pt 1):114-121.
100. Watts BN. Postmenopausal osteoporosis. Obstet Gynecol Survey 1999; 54(8):532-538.
101. Goldstein SR. Selective estrogen receptor modulators: a new category of therapeutic agents for extending the health of postmenopausal women. Am J Obstet Gynecol 1998; 179(6 pt 1):1479-1484.
102. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Int Med 1999; 130(5):431-439.
103. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carboro PP, DeMets DL. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N E Engl J Med 1992; 326(13):852-856.
104. Grey AB, Stapleton JP, Evans MC, Reid IR. The effects of anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metal 1995; 80(11):3191-3195.
105. Van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schonten LJ, Damhuis RA, Botenbal M, Diepenhorst FW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343:448-452.
106. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement:the potential of selective estrogen receptor modulators. Horm Res 1997; 48:155-163.
107. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a three-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE investigators). JAMA 1999, 282(7):637-645.
108. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337(23):1641-1647.
109. Cohen FJ, Watts S, Shah A, Akers R, Plouffe L. Uterine effects of three-year raloxifene therapy in postmenopausal women younger than age 60. Obstet gynecol 2000; 95(1):104-110.
110. Guiliana N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vitro. Bone 1998; 22(5):455-461.
111. Nishikawa M, Akatsu T, Katayama Y, Yatsutomo Y, Kado S, Kugal N, Yamamoto M, Nagata N, Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996; 18(1):9-14.
112. Beauchesne MF, Miller PF. Etidronate and alendronate in the treatment of postmenopausal osteoporosis. Ann Pharmacother 1999; 33:587-598.
113. Watts NB. Treatment of osteoporosis with bisphosphonates. Endocrinol Metab Clin North Am 1998; 27(2):419-439.
114. Lorwood DL. The pharmacology and therapeutic utility of bisphosphonates. Pharmacotherapy 1998; 18:779-789.
115. Rosen CJ, Kessenich CR. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone disease. Drugs 1996; 51:537-551.
116. Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med 1993; 95(suppl 5A):48-52.
117. McClungM, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan Gel-H, Reda C, Yates AJ, Ravn P. Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Int Med 1998; 128(4):253-261.
118. Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four year results from the Early Postmenopausal Intervention Cohort Study: a randomized controlled trial. Ann Intern Med 1999; 131(12):935-942.
119. Bone HG, Adami S, Rizzoli R, Favus M, Ross PD, Santora A, Prahalada S, Daifotis A, Orloff J, Yates J. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 2000; 22(1):15-28.
120. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MN, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Mineral Res 1997; 12(10):1700-1707.
121. Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract Suppl 1999; suppl 100:18-26.
122. Rossini M, Girardello S, Braga V, James G, Adami S. Effects of two intermittent alen dronate regimens in the prevention or treatment of postmenopausal osteoporosis. Bone 2000; 27(1):119-122.
123. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RD, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000; 12(1):1-12.
124. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995; 99:36-42.
125. Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999; 84(9):3076-3081.
126. Mazzzuoli GF, Passeri M, Gennari C, et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 1986; 38(1):3-8.
127. Muff R, Dambacher MA, Fisher JA. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis. Osteoporosis Int 1991; 1(2):72-75.
128. Riggs BL, Hodgson SF, O’Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton J. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322(12):802-809.
129. Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Int Med 1995; 123(6):401-408.
130. Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? N Engl J Med 1987; 316(4):173-177.
131. National Center for Health Statistics. Vital Statistics of the United States. 1992 Volume II Part A. Washington, DC: Public Health Service, 1996. DHHS Publication 96-1101.
132. Stampfer MJ, Colditz GA, Willet WC. Menopause and heart disease: a review. Ann N Y Acad Sci 1990; 592:193-203.
133. Wyeth-Ayerst Laboratories. Advances in HRT for Disease Prevention and Treatment. Slide presentation.
134. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273:199-208.
135. Bush TL, Miller VT. Effects of pharmacologic agents used during menopause. Impact on lipids and lipoproteins. In: Mischell D, ed. Menopause: Physiology and Pharmacology. Chicago, IL: Year Book Medical, 1986:187-208.
136. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravinikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentration and metabolism of plasma lipoproteins. N Engl J Med 1991; 325(17):1196-1204.
137. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995; 38(3):199-210.
138. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988; 115(5):954-963.
139. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75(6):1102-1109.
140. Wagner JD, Clarkson TB, St Clair RW, Schwenke DC, Shively CA, AdamsMR. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 1991; 88(6):1995-2002.
141. Wagner JD, St Clair RW, Schwenke DC, Shively CA, Adams MR, Clarkson TB. Regional differences in arterial low density lipoprotein metabolism in surgically postmenopausal cynomolgus monkeys: effects of estrogen and progesterone replacement therapy. Arteriosclerosis Thrombosis 1992; 12(6):717-726.
142. Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of lowdensity lipoproteins in postmenopausal women. Lancet 1994; 343(8892):269-270.
143. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, Levy RI, Hulley SB. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283(14):1845-1852.
144. Ottosson UB, Carlstrom K, Johansson BG, von Schoultz B. Estrogen induction of liver proteins and high-density lipoprotein cholesterol: comparison between estradiol valerate and ethinyl estradiol. Gynecol Obstet Invest 1986; 22(4):198-205.
145. Barnes RB, Roy S, Lobo RA. Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women. Obstet Gynecol 1985; 66(2):216-219.
146. Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA. A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988(6):1540-1546.
147. Jensen J, Riis BJ, Strom V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 1987; 156(7):66-71.
148. Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985; 151(6):746-750.
149. Orimo A, Inoue S, Ikegami A, Hosoi T, Akishita M, Ouchi Y, Muramatsu M, Orimo H. Vascular smooth muscle cells as target for estrogen. Biochem Biophys Res Commun 1993; 195(2):730-736.
150. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990; 81(5):1680-1687.
151. Magness RR, Rosenfeld CR. Local and systemic estradiol-17Β: effects on uterine and systemic vasodilation. Am J Physiol 1989; 256:536-542.
152. Mugge A, Riedel M, Barton M, Kuhn M, Lichtlen PR. Endothelium independent relaxation of human coronary arteries by 17B-estradiol in vitro. Cardiovasc Res 1993; 27(11):1939-1942.
153. Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994, 89(6):2545-2551.
154. Pines A, Fisman EZ, Levo Y, Averbuch M, Lidor A, Drory Y, Finkelstein A, Hetman-Peri M, Moshkowitz M, Ben-Ari E, et al. The effects of hormone replacement therapy in normal postmenopausal women: measurements of Doppler-derived parameters of aortic flow. Am J Obstet Gynecol 1991; 164(3):806-812.
155. Gangar KF, Vyas S, Whitehead M, Crook D, Meire H, Campbell S. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991; 338(8771):839-842.
156. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of eostrogen on exercise-induced myocardial ischemia in women with coronary artery disease. Lancet 1993; 342(8864):133-136.
157. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90(2):786-791.
158. Gerhard M, Walsh BW, Tawakol A, Haley EA, Creager SJ, Seeley EW, Ganz P, Creager MA. Estradiol therapy combined with progesterone and endotheliumdependent vasodilation in postmenopausal women. Circulation 1998; 98(12):1158-1163.
159. Wilcox JG, Hatch IE, Gentzschein E, Stanczyk FZ, Lobo RA. Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors. Menopause 1997; 67(2):273-277.
160. Mikkola T, Turunen P, Avela K, Orpana A, Viinikka L, Ylikorkala O. 17B-Estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J Clin Endocrinol Metab 1995; 80(6):1832-1836.
161. Hong MK, Romm PA, Reagan K, Green CE, Rackey CE. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol 1992; 69:176-178.
162. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988; 115(5):954-963.
163. Sullivan JM, Zwaag RV, Lemp GF, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988; 108(3):358-363.
164. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994; 73(13):951-952.
165. Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham study. JAMA 1987; 258(9):1183-1186.
166. The Writing Group for the PEPI Trial. Effects of estrogen and estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273(3):199-208.
167. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69:381-387.
168. Lupu F, Bergonzelli GF, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EK. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13(70):1090-1100.
169. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342(8879):1076-1079.
170. Oloffsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10(1):77-82.
171. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawin M, Cannon RO. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336(10):683-690.
172. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994; 84(6):987-995.
173. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vitinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280(7):605-613.
174. Wolf PH, Madans JH, Finucan FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones:evidence from a national cohort. Am J Obstet Gynecol 1991; 164(2):489-494.
175. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A pro spective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985; 313(17):1044-1049.
176. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C. Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336(25):1769-1775.
177. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year followup from the Nurses Health Study. N Engl J Med 1991; 325(11):756-762.
178. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335(7): 453-460.
179. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991(1); 151:75-78.
180. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988, 159(2):312-317.
181. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PN, Siscovick DS, Wagner EH. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154(12):1333-1339.
182. Falkeborn M, Persson I, Adami HO, Bergstrom R, Eaker E, Lithell H, Mohsen R, Naessen T. The risk of acute myocardial infarction after oestrogen and oestrogenprogestogen replacement. Br J Obstet Gynecol 1992; 99(10):821-828.
183. Rosenberg L, Palmer JR, Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol 1993; 137(1):54-63.
184. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: longterm follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987; 70(3 pt. 1):289-293.
185. Newton KM, LaCroix AZ, McKnight B, Knopp RH, Siscovick DS, Heckbert SR, Weiss NS. Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol 1997; 145(3):269-277.
186. Sullivan JM, Vander Zwaag RV, Hughes JP, Maddock V, Kroetz FW. Ramanathan KB, Mirvis DM. Estrogen replacement and coronary artery disease. Effect on survival in post-menopausal women. Arch Intern Med 1990; 150:2557-2562.
187. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Med 1985; 313(17):1038-1043.
188. Eaker ED, Castelli WP. Coronary heart disease and its risk factors among women in the Framingham Study. In: Eaker E, Packard B, Wenger NK, Clarkson TB, Tyroler HA, Eds. Coronary Heart Disease in Women. New York: Haymarket Doyma, 1987:122-132.
189. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease:a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20(1):47-63.
190. Koh KK, Blum A, Hathaway L, Mincemoyer R, Casko G, Waclawiw MA, Panza JA, Cannon RO. Vascular effects of estrogen and vitamin E therapies in postmenopausal women. Circulation 1999; 100(18):1851-1857.
191. De Leo V, La Marca A, Morgante G, Ciani F, Zammarchi E, Setacci C. Low-dose folic acid supplementation reduces plasma levels of the cardiovascular risk factor homocysteine in postmenopausal women. Am J Obstet Gynecol 2000; 183(4):945-947.
192. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and nonste roidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11(4):382-387.
193. DiSaia PJ, Creasman WT. Clinical Gynecologic Oncology. St. Louis, MO: Mosby, 1997:107-167.
194. Gusberg SB, Kardon P. Proliferative endometrial response to thecal granulosa cell tumors. Am J Obstet Gynecol 1971; 111(5):633-643.
195. Norris HJ, Taylor HB. Prognosis of granulosa-theca tumors of the ovary. Cancer 1968; 21(2):255-263.
196. Smith DC, Prentice R, Thompson DJ. Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293:1164-1167.
197. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985; 56:403-412.
198. Chamlian DL, Taylor HB. Endometrial hyperplasia in young women. Obstet Gynecol 1970; 36(5):659-666.
199. Gambrell RD, Teran AZ. Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy. Am J Obstet Gynecol 1991; 165(2):307-315.
200. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer: first of three parts. N Engl J Med 1992; 327(5):319-328.
201. Roy JA, Sawka CA, Pritchard KI. Hormone replacement therapy in women with breast cancer: do the risks outweigh the benefits? J Clin Oncol 1996; 14(3):997-1006.
202. Miller, et al., eds. SEER Cancer Statistics Review 1973-1993. National Cancer Institute, 1997.
203. Miller BA, Feuer EJ, Hankey BF. [Letter]. N Engl J Med 1992; 327(24):1756-1757.
204. Feuer EJ, Wun L-M, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993; 85(11):892-897.
205. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992; 79(2):286-294.
206. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993; 168(5):1473-1480.
207. Steinberg KK, Thacker SB, Stroup DF, Zack MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265(15):1985-1990.
208. Dupont WD, Page DL.Menopausal estrogen replacement therapy and breast cancer. Arch Int Med 1991; 151:67-72.
209. Armstrong BK. Oestrogen therapy after the menopause-boon or bane? Med J Aus 1988; 148:213-214.
210. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321(5):293-297.
211. Hulka BS, Chambless LE, Deubner DC, Wilkinson WE. Breast cancer and estrogen replacement therapy. Am J Obstet Gynecol 1982;143(6):638-644.
212. DiSaia PJ, Grosen EA, Odicino F, Cowan B, Pecorelli S, Wile AG, Creasman WT. Replacement therapy for breast cancer survivors: a pilot study. Cancer 1995; 76(10 suppl):2075-2078.
213. Fisher B, Dignam J, Bryant J, DeCillis A, Wickham DL, Wolmark N, Constantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldham MI, Farrar W, Evans J, Lickley HL. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88:1529-1542.
214. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieland S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90(18):1371-1388.
215. Cauley JA, Norton L, Lippman ME, Eckert S, Kreuger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Dowles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: four-year results from the MORE Trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65(2):125-134.
216. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348(9033):981-983.
217. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolus in women. Lancet 1996; 348(9033):983-987.
218. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348:977-980.
219. Devor M, Barrett-Connor E, Renvall M, Feigal D, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92:275-282.
220. Saleh AA, Dorey LG, Dombrowski MP, Ginsburg KA, Hirokawa S, Kowalczyk C, Hirata J. Bottoms S, Cotton DB, Mammen EF. Thrombosis and hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 1993; 169(6):1554-1557.
221. American Cancer Society. Cancer Facts and Figures. 1997.
222. Grodstein F, Martinez E, Platz EA, Giovannucci E, Colditz GA, Kautzky M, Fuchs C, Stampfer MS. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998; 128(9):705-712.
223. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995; 87(7):517-523.
224. Murakami H, Hasui H. Hormonal control of human colon carcinoma cell growth in serum-free medium. Proc Natl Acad Sci USA 1980; 77:3464-3468.
225. Lointier P, Wildrick DM, Boman BM. The effects of steroid hormones on human colon cancer cell line in vitro. Anticancer Res 1992; 12:1327-1330.
226. Jorm AF, Koren AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76:465-479.
227. Evans DA, Funkenstein H, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. Prevalence of Alzheimer’s disease in a community population of older persons: higher than previously reported. JAMA 1989; 262:2551-2556.
228. Bachman DL, Wolf PA, Linn R, Knoefer JE, Cobb J, Belanger A, D’Agostino RB, White LR. Prevalence of dementia and probable senile dementia of the Alzheimer’s type in the Framingham Study. Neurology 1992; 42(1):115-119.
229. Henderson VW. Estrogen and Alzheimer’s disease: current status. Menopausal Med 1999; 7(1):1-5.
230. Henderson VW. Estrogen, cognition, and a woman’s risk of Alzheimer’s disease. Am J Med 1997; 103(suppl 3A):11-18.
231. Brinton RD, Tran J, Profitt P, Montoya M. 17B-Estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem Res 1997; 22(11):1339-1351.
232. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer’s disease. Arch Intern Med 1996; 156(19):2213-2217.
233. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer’s disease in women. Am J Epidemiol 1994; 140(3):256-261.
234. Szklo M, Cerhan J, Diez-Roux AV, Chambless L, Cooper L, Folsom AR, Fried LP, Knopman D, Nieto FJ. Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk Communities (ARIC) Study. Am J Epidemiol 1996; 144(11):1048-1057.
235. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993; 269(20):2637-2641.
236. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer’s disease: a randomized controlled trial. JAMA 2000; 283(8):1007-1015.
237. National Center for Health Statistics. Vital Statistics of the United States 1992. Vol. 2. Part A. Washington, DC: Public Health Service, 1996. DHHS publication 96-1101.
238. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. Br Med J 1988; 297(6647):519-522.
239. Longstreth WT Jr, Nelson LM, Koepsell TD, van Belle G. Subarachnoid hemorrhage and hormonal factors in women: a population-based case-control study. Ann Intern Med 1994; 121:168-173.
240. Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden. Arch Intern Med 1993; 153(10):1201-1209.
241. Pedersen AT, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk on non-fatal stroke. Lancet 1997; 350:1277-1283.
242. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinmen JC. Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med 1993; 153:73-79.
243. The Eye-Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 1992; 110:1701-1708.
244. Vingerling JR, Dielemans I, Witteman JC, Hofman A, Grobbee DE, de Jong DT.Macular degeneration and early menopause: a case-control study. Br Med J 1995; 310(6994):1570-1571.
245. Klein BE, Klein R, Jensen SC, Ritter LL. Are sex hormones associated with age-related maculopathy in women? The Beaver Dam Eye Study. Trans Am Ophthalmol Soc 1994; 92:289-295.
246. Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? N Engl J Med 1987; 316(4):173-177.
247. Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tanenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990; 323:878-883.
248. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 1995; 98:331-335.
249. Recker RR, Hinders S, Davies KM, Heaney RP. Stegman MR, Lappe JM, Kimmel DB. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996; 11:1961-1966.
250. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338(11):736-746.
251. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Br Med J 1994; 308:1081-1082.
252. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 1997; 337:670-676.
253. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM, Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. Ann Intern Med 1996; 124:400-406.
254. Goldstein SR, Zeltser I, Horan C, Snyder JR, Schwartz LB. Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am J Obstet Gynecol 1997; 177(1):102-108.
255. Riig LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. N Engl J Med 1978; 298(4):195-197.
256. American College of Obstetricians and Gynecologists. ACOG Educational Bulletin:Hormone Replacement Therapy. Washington, DC: American College of Obstetricians and Gynecologists, May 1998:516-525. Compendium of Selected Publications.
257. Speroff L, Glass RH, Kase NG. Postmenopausal hormone therapy. In: Clinical Gynecologic Endocrinology and Infertility. 6th ed. Baltimore: Lippincott, Williams and Wilkins, 1999:725-779.
258. Lobo RA, McCormick W, Singer F, Roy S. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Am J Obstet Gynecol 1984; 63(1):1-5.
259. David A, Don R, Trajchner G, Weissglas L. Veralipride: alternative antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol 1988; 158(5):1107-1115.
260. Melis GB, Gambacciani M, Cagnacci A, Paoletti AM, Mais V, Fioretti P. Effects of the dopamine antagonist veralipride on hot flushes and leutinizing hormone secretion in postmenopausal women. Obstet Gynecol 1988; 72:688-692.
261. Lebherz TB, French LT. Nonhormonal treatment of the menopausal syndrome. A double-blind evaluation of an autonomic system stabilizer. Obstet Gynecol 1969; 33:795-799.
262. Nesheim BI, Saetre T. Reduction of menopausal hot flushes by methyldopa: a double blind crossover trial. Eur J Clin Pharmacol 1981; 20:413-416.
263. Loprinzi CL, Pisansky TM, Fonesca R, Sloan JA, Zahasky KM, Quella SK, Novotny PJ, Rommans TA, Dumesic DA, Perez EA. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998; 16(7):2377-2381.
264. Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR. Fidler P, Stella PJ, Swan DK, Vaught NL, Novotny P. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998; 16(2):495-500.
265. American Society for Reproductive Medicine. Status of Environmental and Dietary Estrogens-Are They Significant Estrogens? A Practice Committee Report; An Educational Bulletin, August 2000:1-5.
266. North American Menopause Society. The role of isoflavones in menopausal health:consensus opinion of the North American Menopause Society. Menopause 2000; 7:215-229.